

PROFILE

Founded in 1998, TSO₃ has made its mission the development and commercialization of innovative and comprehensive solutions for sterilization.

The Company has developed a unique sterilization process that uses ozone as the sterilizing agent. Efficacious, fast, economical and environment friendly, this process is safe for both the users and the patients, and responds perfectly to the new needs in sterilization.

The first product resulting from this technological platform is the *125L Ozone Sterilizer* (named for its 125-litre/4-cubic-foot capacity), a large-capacity sterilizer developed for general usage and designed for all hospital settings. This reliable and easy-to-use device allows the efficacious sterilization of surgical and diagnostic instruments sensitive to heat and moisture.

The *125L Ozone Sterilizer* is cleared for commercialization by Health Canada and by the UNITED STATES Food and Drug Administration (FDA).

TSO₃ currently has 54 employees, including 16 on the sales and marketing team. TSO₃ became a publicly owned company on August 30, 2001, with an Initial Public Offering of \$5 million. An additional \$35 million was raised through subsequent rounds of financing. Shares are now traded on the Toronto TSX under the symbol TOS.